Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone payment was ...

Is Recursion Pharma a buy because of Nvidia’s endorsement? Indeed, Nvidia’s bet on Recursion is notable, but despite the stake and collaboration, the name isn’t without its fair share of risks.

Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Self-Referential Large Models: Recursive Self-Enhancement in Code Generation ...

Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia –– Extends Cash Runway through 2027 –NEW ...

This article presents analytical, Monte Carlo, and empirical evidence on combining recursive and rolling forecasts when linear predictive models are subject to structural change. Using a ...

The Real Brokerage Inc. (NASDAQ:REAX) is one of the 10 Best Penny Stocks to Buy for the Next 5 Years. On August 6, The Real ...

The most profound failures in history are not those that bet big and lost, but those that failed to bet at all. Incremental advances will never cure Alzheimer’s disease or reverse climate change. To ...

Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 apiece after investors mimicked the recent selling of three company executives.

New research explores how prolonged AI interactions can, at least for some users, start to blur the lines between reality and fantasy. Simple interventions could prevent tragic outcomes.